title: In vivo assessment of the vascular disrupting effect of M410 by DCE-MRI biomarker in a rabbit model of liver tumor.
abstract: The present study aimed to prospectively monitor the vascular disrupting effect of M410 by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in rabbits with VX2 liver tumors. Twenty-eight rabbits bearing VX2 tumors in the left lobe of the liver were established and randomly divided into treatment and control groups, intravenously injected with 25 mg/kg M410 or sterile saline, respectively. Conventional and DCE-MRI data were acquired on a 3.0-T MR unit at pretreatment, 4 h, 1, 4, 7 and 14 days post-treatment. Histopathological examinations [hematoxylin and eosin (H&E) and CD34 immunohistochemisty staining] were performed at each time point. The dynamic changes in tumor volume, kinetic DCE-MRI parameter [volume transfer constant (Ktrans)] and histological data were evaluated. Tumors grew slower in the M410 group 4-14 days following treatment, compared with rapidly growing tumors in the control group (P<0.05). At 4 h, 1 and 4 days, Ktrans significantly decreased in the M410 group compared with that in the control group (P<0.05). However, Ktrans values were similar in the two groups for the other time points studied. The changes in DCE-MRI parameters were consistent with the results obtained from H&E and CD34 staining of the tumor tissues. DCE-MRI parameter Ktrans may be used as a non-invasive imaging biomarker to monitor the dynamic histological changes in tumors following treatment with the vascular targeting agent M410.
authors.affiliation: Department of Radiology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, P.R. China.
authors.forename: Rui-Meng
authors.initials: RM
authors.lastname: Yang
authors.affiliation: Guangzhou Institute of Chemistry, Chinese Academy of Science, Guangzhou 510650, P.R. China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Zou
authors.affiliation: Department of Radiology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, P.R. China.
authors.forename: Dan-Ping
authors.initials: DP
authors.lastname: Huang
authors.affiliation: Department of Medical Equipment, Guangdong Food and Drug Vocational College, Guangzhou 510520, P.R. China.
authors.forename: Sheng-Sheng
authors.initials: SS
authors.lastname: Lai
authors.affiliation: Department of Radiology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, P.R. China.
authors.forename: Xiang-Dong
authors.initials: XD
authors.lastname: Xu
authors.affiliation: Department of Radiology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, P.R. China.
authors.forename: Xin-Hua
authors.initials: XH
authors.lastname: Wei
authors.affiliation: Department of Radiology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, P.R. China.
authors.forename: Han-Zheng
authors.initials: HZ
authors.lastname: Chang
authors.affiliation: Guangzhou Institute of Chemistry, Chinese Academy of Science, Guangzhou 510650, P.R. China.
authors.forename: Tong-Kun
authors.initials: TK
authors.lastname: Huang
authors.affiliation: Department of Radiology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, P.R. China.
authors.forename: Li
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Radiology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, P.R. China.
authors.forename: Wen-Jie
authors.initials: WJ
authors.lastname: Tang
authors.affiliation: Department of Radiology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, P.R. China.
authors.forename: Xin-Qing
authors.initials: XQ
authors.lastname: Jiang
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000138:chemical synthesis / Q000493:pharmacokinetics; D000818:Animals; D001632:Bibenzyls / Q000008:administration & dosage* / Q000138:chemical synthesis / Q000493:pharmacokinetics; D014408:Biomarkers, Tumor / Q000378:metabolism; D045744:Cell Line, Tumor; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy / Q000473:pathology*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D010755:Organophosphates / Q000008:administration & dosage* / Q000138:chemical synthesis / Q000493:pharmacokinetics; D011817:Rabbits; D013267:Stilbenes / Q000008:administration & dosage* / Q000138:chemical synthesis / Q000493:pharmacokinetics
chemical_list: C000595054:3,4',5-trimethoxylstilbene-3'-O-phosphate; D020533:Angiogenesis Inhibitors; D001632:Bibenzyls; D014408:Biomarkers, Tumor; D010755:Organophosphates; D013267:Stilbenes; C040105:combretastatin